StockNews.AI
SNDX
StockNews.AI
139 days

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

1. Syndax CEO to speak at Stifel 2025 Oncology Forum. 2. The event will showcase Syndax's cancer therapies and clinical trials. 3. Live webcast available, promoting investor engagement in Syndax. 4. Syndax's pipeline includes FDA-approved cancer therapies Revuforj® and Niktimvo™.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in notable forums typically boosts investor confidence. Historical examples show similar events led to stock price rallies.

How important is it?

The announcement signals active engagement in oncology, potentially attracting investor attention.

Why Short Term?

The event's immediate visibility could enhance short-term investor interest and stock activity.

Related Companies

VRTXAKBACLLS
April 02, 2025 07:00 ET  | Source: Syndax Pharmaceuticals, Inc. NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn. Syndax Contacts Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827 SNDX-G

Related News